Incyte Corporation (INCY)
NASDAQ: INCY
· Real-Time Price · USD
62.21
-0.45 (-0.72%)
At close: May 01, 2025, 12:08 PM
-0.72% (1D)
| Bid | 62.15 |
| Market Cap | 12.04B |
| Revenue (ttm) | 4.41B |
| Net Income (ttm) | 21.27M |
| EPS (ttm) | 0.15 |
| PE Ratio (ttm) | 414.73 |
| Forward PE | 9.61 |
| Analyst | Hold |
| Ask | 62.2 |
| Volume | 978,378 |
| Avg. Volume (20D) | 2,068,634 |
| Open | 62.02 |
| Previous Close | 62.66 |
| Day's Range | 61.05 - 62.64 |
| 52-Week Range | 52.28 - 83.95 |
| Beta | 0.90 |
About INCY
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chr...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 4, 1993
Employees 2,617
Stock Exchange NASDAQ
Ticker Symbol INCY
Website https://www.incyte.com
Analyst Forecast
According to 20 analyst ratings, the average rating for INCY stock is "Hold." The 12-month stock price forecast is $72, which is an increase of 15.74% from the latest price.
Stock ForecastsEarnings Surprise
Incyte has released their quartely earnings
on Apr 29, 2025:
2 days ago
+1.53%
INCY stock has given up its prior gain. Incyte sha...
Unlock content with
Pro Subscription
2 days ago
+1.53%
Incyte shares are trading higher after the company reported better-than-expected Q1 financial results
